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N-alkyl-substituted isatins enhance P2X7 receptor-induced interleukin-1β
interleukin-1 release
from murine macrophages
Abstract
Extracellular adenosine 5′-triphosphate (ATP) activates the P2X7 receptor channel to induce the rapid
release of the proinflammatory cytokine, interleukin- (IL-) 1β, from macrophages. Microtubule
rearrangements are thought to be involved in this process. Some isatin derivatives alter microtubules and
display anticancer activities. The current study investigated the effect of isatin and seven structurally
diverse isatin derivatives on P2X7-mediated IL-1β release from murine J774 macrophages. ATP-induced
IL-1β and lactate dehydrogenase (LDH) release were assessed by specific colorimetric assays. P2X7
activity was determined by flow cytometric measurements of ATP-induced cation dye uptake. Cytotoxicity
of isatin derivatives was determined using a tetrazolium-based colorimetric assay. ATP caused rapid
IL-1β release in a concentration-dependent manner, and this process was completely impaired by the
P2X7 antagonist, AZ10606120. In contrast, 5,7-dibromo-N-(p-methoxybenzyl)isatin (NAI) and
3-4-[5,7-dibromo-1-(4-methoxybenzyl)-2-oxoindolin-3-ylidenamino]phenylpropanoic acid (NAI-imine)
enhanced P2X7-induced IL-1β release by twofold compared to that of isatin and the parent molecule,
5,7-dibromoisatin. NAI and NAI-imine had minimal effect on P2X7-induced dye uptake and LDH release. In
contrast, 24-hour incubation with NAI and NAI-imine (in the absence of exogenous ATP) induced
macrophage death in a concentration-dependent manner. In conclusion, this study demonstrates that Nalkyl-substituted isatins enhance P2X7 receptor-induced IL-1β release from murine macrophages. Thus,
in addition to direct anticancer effects, these compounds may also impact inflammatory and immune
cells within the tumor microenvironment.
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Extracellular adenosine 5 -triphosphate (ATP) activates the P2X7 receptor channel to induce the rapid release of the proinflammatory cytokine, interleukin- (IL-) 1𝛽, from macrophages. Microtubule rearrangements are thought to be involved in this process.
Some isatin derivatives alter microtubules and display anticancer activities. The current study investigated the effect of isatin and
seven structurally diverse isatin derivatives on P2X7-mediated IL-1𝛽 release from murine J774 macrophages. ATP-induced IL1𝛽 and lactate dehydrogenase (LDH) release were assessed by specific colorimetric assays. P2X7 activity was determined by flow
cytometric measurements of ATP-induced cation dye uptake. Cytotoxicity of isatin derivatives was determined using a tetrazoliumbased colorimetric assay. ATP caused rapid IL-1𝛽 release in a concentration-dependent manner, and this process was completely
impaired by the P2X7 antagonist, AZ10606120. In contrast, 5,7-dibromo-N-(p-methoxybenzyl)isatin (NAI) and 3-{4-[5,7-dibromo1-(4-methoxybenzyl)-2-oxoindolin-3-ylidenamino]phenyl}propanoic acid (NAI-imine) enhanced P2X7-induced IL-1𝛽 release by
twofold compared to that of isatin and the parent molecule, 5,7-dibromoisatin. NAI and NAI-imine had minimal effect on P2X7induced dye uptake and LDH release. In contrast, 24-hour incubation with NAI and NAI-imine (in the absence of exogenous ATP)
induced macrophage death in a concentration-dependent manner. In conclusion, this study demonstrates that N-alkyl-substituted
isatins enhance P2X7 receptor-induced IL-1𝛽 release from murine macrophages. Thus, in addition to direct anticancer effects, these
compounds may also impact inflammatory and immune cells within the tumor microenvironment.

1. Introduction
The P2X7 receptor is a trimeric ligand-gated cation channel,
which upon activation by its natural ligand, extracellular
adenosine 5 -triphosphate (ATP), results in the rapid flux
of cations including fluorescent dyes such as ethidium+ [1].
P2X7 is highly expressed on monocytes and macrophages
and has central roles in inflammation and immunity [2, 3],
largely in part, through the release of the proinflammatory
cytokine, interleukin- (IL-) 1𝛽 [4]. P2X7 activation can induce
IL-1𝛽 release by a number of nonclassical secretion pathways involving secretory lysosomes, microvesicles, exosomes,
autophagosomes, and cell death [5]. However, P2X7-induced
IL-1𝛽 release can occur prior to [6] or in the absence of cell
death [7]. At a molecular level, microtubule rearrangements

are involved in P2X7-induced IL-1𝛽 release. The microtubule destabilizer, colchicine, can impair P2X7-induced IL1𝛽 release from murine microglia [8] and macrophages [9].
Moreover, the microtubule disrupting agent, nocodazole, as
well as the histone deacetylase inhibitors, suberoylanilide
hydroxamic acid and ITF2357 (which impair tubulin hyperacetylation), can prevent P2X7-induced IL-1𝛽 release from
human monocytes [10]. In contrast, the microtubule stabilizing agent, paclitaxel (Taxol), augments P2X7-induced IL-1𝛽
release from these cells [10].
Isatin (1H-ondole-2,3-dione) is an endogenous molecule
found in plants and animals including humans and other
mammals [11]. In the tissues of mammals, isatin concentrations vary from <0.1 to 10 𝜇M [11]. Due to the synthetic versatility of isatin, modification of this compound has resulted
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in the generation of a large number of isatin derivatives,
which demonstrate a diverse array of antimicrobial, antiinflammatory, anticonvulsant, and anticancer properties [12–
14]. The biological targets of isatin derivatives are varied
and include proteases, kinases, and caspases [15]. Moreover,
Vine and colleagues have generated a number of N-alkylated
isatin derivatives with potent cytotoxic activity against tumor
cells, which act by binding to tubulin and destabilizing
microtubules [16]. Therefore, given the potential role of the
microtubule network in P2X7-mediated IL-1𝛽 release, the
current study investigated the effect of a panel of isatin
derivatives on P2X7-mediated IL-1𝛽 release from murine J774
macrophages.

2. Material and Methods
2.1. Materials. RPMI-1640 medium and GlutaMAX were
from Life Technologies (Grand Island, USA). Fetal calf
serum was from Bovogen Biologicals (Keilor East, Australia).
Lipopolysaccharide (LPS) (Escherichia coli serotype 055:B5)
and ATP were from Sigma Chemical Co. (St. Louis, USA). N[2-[[2-[(2-Hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]-2-tricyclo[3.3.1.13,7]dec-1-ylacetamide dihydrochloride
(AZ10606120) was from Tocris Bioscience (Ellisville, USA).
Isatin and 5-bromoisatin were from Aldrich Chemical Co.
(Milwaukee, USA). 5-Fluoroisatin was from Alfa Aesar Co.
(Ward Hill, USA). 5,7-Dibromoisatin, 5-nitroisatin, and
1N-methylisatin were prepared as described in [17]. 5,7Dibromo-N-(p-methoxybenzyl)isatin (NAI) was prepared as
described in [18]. 3-{4-[5,7-Dibromo-1-(4-methoxybenzyl)2-oxoindolin-3-ylidenamino]phenyl}propanoic acid (NAIimine) was prepared as described in [19, 20]. Dimethyl
sulfoxide (DMSO) and ethidium bromide were from Amresco (Solon, USA). CellTiter 96 AQUEOUS One Solution was
from Promega Corporation (Madison, USA).
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the Cytotoxicity Detection KitPLUS (Roche, Mannheim, Germany) according to the manufacturer’s instructions. LDH
release is presented as a percentage of maximal LDH release.
2.4. Ethidium+ Uptake Assay. Cells in flasks, cultured to an
equivalent cell density to that of cells in the IL-1𝛽/LDH release
assays, were incubated for 4 h with 1 𝜇g/mL LPS in complete medium. Cells were harvested by mechanical scraping
and washed three times with physiological medium. ATPinduced ethidium+ uptake into cells suspended in physiological medium at 37∘ C was determined using a flow cytometric
assay as described in [21].
2.5. Cytotoxicity Assay. Experiments were performed as
described in [22] with the following modifications. Cells
in complete medium in 96-well flat bottom plates (5 ×
103 cells/100 𝜇L/well) were incubated overnight at 37∘ C/5%
CO2 . The medium was removed and the cells incubated for 4 h with 1 𝜇g/mL LPS in complete medium
(100 𝜇L/well). Cells were washed once with RPMI-1640
medium (200 𝜇L/well) and then incubated with compounds
(as indicated) for 24 h at 37∘ C/5% CO2 (100 𝜇L/well). Finally,
cells were incubated with CellTiter 96 AQUEOUS One Solution (20 𝜇L/well) for 2 h at 37∘ C/5% CO2 and the absorbance
was measured at 490 nm.
2.6. Data Presentation and Statistics. Data are presented as
mean ± SD. Differences between treatments were compared
by ANOVA (using Tukey’s posttest) using Prism 5 for Mac
OS X (Version 5.0a; GraphPad Software, San Diego, USA).
Concentration response curves were fitted to a sigmoidal
dose response using the least squares (ordinary) fit method
of Prism 5 for Mac OS X.

3. Results
2.2. Cells. The murine macrophage cell line, J774 (American
Type Culture Collection, Rockville, USA), was maintained
in complete medium (RPMI-1640 medium containing 2 mM
GlutaMAX and 10% heat-inactivated fetal calf serum) at
37∘ C/5% CO2 .
2.3. IL-1𝛽 and Lactate Dehydrogenase Release Assays. Cells in
complete medium in 24-well plates (5 × 105 cells/1 mL/well)
were incubated overnight at 37∘ C/5% CO2 . The medium was
removed and the cells incubated for 4 h with 1 𝜇g/mL LPS
in complete medium (1 mL/well). Cells were then washed
three times with physiological medium (147 mM NaCl, 2 mM
KCl, 2 mM CaCl2 , 1 mM MgCl2 , and 10 mM HEPES; pH 7.4).
Cells were finally preincubated for 30 min in the absence
or presence of compound (as indicated) in physiological
medium (0.5 mL/well) and then incubated for 20 min in the
absence or presence of ATP (as indicated). The samples were
centrifuged (11,000 ×g for 30 s) and the cell-free supernatants
were stored at −80∘ C until required. IL-1𝛽 concentration was
measured using the Mouse IL-1𝛽 ELISA MAX Deluxe Set
(BioLegend, San Diego, USA) according to the manufacturer’s instructions. Lactate dehydrogenase (LDH) activity in
cell-free supernatants and cell lysates was measured using

3.1. P2X7 Activation Induces IL-1𝛽 Release. P2X7 activation
can induce IL-1𝛽 release from the J774 macrophage cell
line following priming with LPS [23, 24]. To confirm these
previous observations, LPS-primed J774 cells were incubated
in the absence or presence of 1, 3, or 5 mM ATP, and
the amount of IL-1𝛽 release was measured by ELISA. At
each concentration examined, ATP induced significant IL-1𝛽
release from cells compared to cells incubated in the absence
of ATP (Figure 1(a)). IL-1𝛽 release was maximal at 3 mM ATP
(Figure 1(a)) and thus was used for subsequent studies.
To confirm further that P2X7 activation induces IL-1𝛽
release from J774 cells, LPS-primed J774 cells were preincubated in the absence or presence of the specific P2X7
antagonist, AZ10606120 (10 𝜇M) [25], prior to incubation
with 3 mM ATP. ATP induced significant IL-1𝛽 release from
cells compared to cells incubated in the absence of ATP
(Figure 1(b)). Preincubation with AZ10606120 completely
impaired the ATP-induced IL-1𝛽 release from these cells
(Figure 1(b)). Basal IL-1𝛽 release in the absence or presence
of AZ10606120 was similar (Figure 1(b)). ATP induced a
small but significant amount of LDH release from cells
(average ATP-induced LDH release of 1.32%) compared to
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Figure 1: P2X7 activation induces IL-1𝛽 release. LPS-primed J774 cells in physiological medium were preincubated in the absence or presence
of 10 𝜇M AZ10606120 for 30 min and then in the absence (basal) or presence of (a) 1, 3, or 5 mM ATP or ((b) and (c)) 3 mM ATP for 20 min.
((a) and (b)) The IL-1𝛽 concentration in cell-free supernatants was measured using an ELISA. (c) The LDH activity in cell-free supernatants
and cell lysates was measured using a cytotoxicity kit, and results are expressed as a percentage of maximal LDH release from lysed cells. ((a)
to (c)) Results are mean ± SD (𝑛 = 3); ∗ 𝑃 < 0.05 or ∗∗∗ 𝑃 < 0.001 compared with corresponding basal; †† 𝑃 < 0.01 or ††† 𝑃 < 0.001 compared
with ATP alone.

cells incubated in the absence of ATP (Figure 1(c)). This
ATP-induced LDH release was near completely prevented
by preincubation with AZ10606120 (Figure 1(c)). Basal LDH
release in the absence or presence of AZ10606120 was similar
(Figure 1(c)). Thus, P2X7 activation induces IL-1𝛽 release

from LPS-primed J774 cells, which may in part be a result of
cell lysis.
3.2. NAI and NAI-Imine Increase P2X7-Mediated IL-1𝛽
Release in a Concentration-Dependent Manner. To determine
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3.3. NAI and NAI-Imine Have Minimal Effect on P2X7Mediated LDH Release and Ethidium+ Uptake. Both NAI
and NAI-imine were originally identified as potent cytotoxic drugs [18, 19]. Therefore, to determine if either of
these compounds enhanced P2X7-mediated IL-1𝛽 release by
cytotoxicity, LPS-primed J774 cells were preincubated in the
presence of DMSO, 1 𝜇M NAI, or 1 𝜇M NAI-imine prior to
incubation with 3 mM ATP, and the subsequent release of IL1𝛽 and LDH was measured from the same supernatants. As
above (Figures 2 and 3), NAI and NAI-imine increased ATPinduced IL-1𝛽 release by approximately twofold (Figure 4(a)).
Basal IL-1𝛽 release in the presence of DMSO or either isatin
derivative was similar (Figure 4(a)). ATP induced a small
but significant amount of LDH release from LPS-primed
J774 cells compared to cells incubated with DMSO alone
(Figure 4(b)). Preincubation with NAI-imine, but not NAI,
induced a small but significant increase in ATP-induced
LDH release (average ATP-induced LDH release of 1.74% and
1.58%, resp.) compared to cells incubated with both DMSO
and ATP (average ATP-induced LDH release of 0.94%)
(Figure 4(b)). Basal LDH release in the presence of DMSO
or either isatin derivative was similar (Figure 4(b)).
To determine if NAI or NAI-imine enhanced P2X7induced IL-1𝛽 release by increasing P2X7 activity, LPSprimed J774 cells were preincubated in the presence of
DMSO, 1 𝜇M NAI, or 1 𝜇M NAI-imine before flow cytometric
measurements of 3 mM ATP-induced ethidium uptake+ . ATP
induced significant ethidium uptake+ into cells compared
to cells incubated in the absence of ATP (Figure 4(c)).
Neither NAI nor NAI-imine altered ATP-induced ethidium
uptake+ into cells (Figure 4(c)). Basal ethidium uptake+ in
the presence of DMSO or either isatin derivative was similar
(Figure 4(c)).
3.4. NAI and NAI-Imine Induce Cytotoxicity in a Concentration-Dependent Manner. As stated above, NAI and NAIimine are potent cytotoxic drugs. Therefore, to determine
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if isatin or isatin derivatives modulate P2X7-mediated IL1𝛽 release, LPS-primed J774 cells were preincubated in
the presence of DMSO (diluent control), isatin, or various
isatin derivatives (each at 1 𝜇M) prior to incubation with
3 mM ATP. ATP induced significant IL-1𝛽 release from cells
compared to cells incubated in the presence of DMSO alone
(Figure 2). Preincubation with isatin or five isatin derivatives
failed to modulate ATP-induced IL-1𝛽 release (Figure 2). In
contrast, the N-alkylated isatin derivatives, NAI and NAIimine, increased ATP-induced IL-1𝛽 release by approximately
twofold that of DMSO, isatin, and the other isatin derivatives
including the parent molecule, 5,7-dibromoisatin (Figure 2).
To further assess if the NAI and NAI-imine effect was
concentration dependent, LPS-primed J774 cells were preincubated in the presence of increasing concentrations of these
two isatin derivatives prior to incubation with 3 mM ATP.
Both NAI and NAI-imine increased ATP-induced IL-1𝛽
release in a concentration-dependent manner with maximum
release observed at 1 𝜇M for both compounds (Figures 3(a)
and 3(b)) and with EC50 values of 106 ± 12 nM and 407 ±
112 nM, respectively (Figure 3(c)).
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ATP

Figure 2: NAI or NAI-imine increase P2X7-mediated IL-1𝛽 release.
LPS-primed J774 cells in physiological medium were preincubated
in the presence of DMSO, or 1 𝜇M isatin or isatin derivative (as
indicated) for 30 min, and then in the absence or presence of 3 mM
ATP for 20 min. The IL-1𝛽 concentration in cell-free supernatants
was measured using an ELISA. Results are mean ± SD (𝑛 = 3-4);
∗∗
∗∗∗
††
𝑃 < 0.01 or 𝑃 < 0.001 compared with DMSO alone; 𝑃 < 0.01
or ††† 𝑃 < 0.001 compared with DMSO and ATP.

if these compounds induce cytotoxicity in J774 cells, LPSprimed J774 cells were incubated for 24 h in the presence of
DMSO or increasing concentrations of NAI and NAI-imine,
and cytotoxicity was indirectly assessed by measurements
of cell viability using a tetrazolium-based assay. ATP, which
induces detectable death in J774 cells in 2 to 6 h [26, 27], was
used as a positive control and for comparison. As expected,
ATP induced cytotoxicity in a concentration-dependent
manner, with a half maximal inhibitory concentration (IC50 )
value of 596 ± 34 𝜇M and with maximal cell death induced
at 3 mM ATP (Figure 5). NAI and NAI-imine also induced
cytotoxicity in a concentration-dependent manner, with IC50
values of 279 ± 9 nM and 442 ± 105 nM, respectively, up
to three orders of magnitude greater than ATP and with
maximal cell death induced at 10 𝜇M for both compounds
(Figure 5).

4. Discussion
The current study demonstrates that the N-alkyl-substituted
isatins, NAI and NAI-imine, enhance P2X7-induced but
not basal IL-1𝛽 release from LPS-primed murine J774
macrophages. In contrast NAI and NAI-imine did not
enhance P2X7-induced dye uptake (pore formation) indicating that the effect of these compounds on ATP-induced IL1𝛽 release was downstream of P2X7 activation. In contrast,
others have shown that the histamine H1 receptor antagonist, clemastine, enhances both ATP-induced IL-1𝛽 release
from human monocytes and ATP-induced dye uptake into
HEK-293 cells expressing human P2X7 [28]. Similarly, the
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Figure 3: NAI or NAI-imine increase P2X7-mediated IL-1𝛽 release in a concentration-dependent manner. LPS-primed J774 cells in
physiological medium were preincubated in the presence of ((a) and (b)) DMSO or (a) NAI or (b) NAI-imine (as indicated) for 30 min
((a) and (b)) and then in the absence or presence of 3 mM ATP for 20 min. The IL-1𝛽 concentration in cell-free supernatants was measured
using an ELISA. (c) The percentage of maximal increase in ATP-induced IL-1𝛽 release was determined from (a) and (b). ((a) to (c)) Results
are mean ± SD (𝑛 = 3); ∗ 𝑃 < 0.05, ∗∗ 𝑃 < 0.01, or ∗∗∗ 𝑃 < 0.001 compared with DMSO alone; † 𝑃 < 0.05 and ††† 𝑃 < 0.001 compared with
DMSO and ATP.

anesthetic, sevoflurane, enhances both ATP-induced caspase1 activation (which mediates P2X7-induced IL-1𝛽 release in
J774 macrophages [23]) and ATP-induced dye uptake into
J774 macrophages [29]. Finally, the cyclooxygenase inhibitor,
tenidap, and a ginsenoside metabolite of the Chinese herb,
Ginseng, can also enhance ATP-induced dye uptake into
J774 macrophages [30, 31], although the impact of these
compounds on ATP-induced IL-1𝛽 release was not reported.
Thus, the current study demonstrates that NAI and NAIimine can enhance P2X7-induced IL-1𝛽 release in the absence
of altered P2X7 activation, describing a novel mechanism
by which these compounds can enhance P2X7-induced IL1𝛽 release from macrophages. It remains to be determined if
NAI and NAI-imine can enhance P2X7-induced IL-1𝛼 or IL18 release from J774 macrophages, IL-1 family cytokines, that

are also released from murine macrophages following P2X7
activation [23].
In the current study, P2X7-induced IL-1𝛽 release from
J774 macrophages was associated with a small amount of
LDH release (cytolysis). However, NAI and NAI-imine had
no or minimal effect on P2X7-induced LDH release, respectively. Previous studies have demonstrated that P2X7-induced
IL-1𝛽 release from primary murine macrophages and human
monocytes can occur prior to [6] or in the absence of cell
death [7], respectively. Furthermore, Vine and colleagues
have described the mechanism for N-alkylisatin-induced cell
death to be caspase-3/7 dependent in human cancer cell
lines [18] indicating that these compounds mediate apoptosis
rather than necrosis. Collectively, this suggests that the
mechanism by which NAI and to a large extent NAI-imine
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Figure 4: NAI or NAI-imine increase P2X7-mediated IL-1𝛽 release but not ethidium+ uptake. LPS-primed J774 cells in physiological medium
were preincubated in the presence of DMSO, or 1 𝜇M NAI or 1 𝜇M NAI-imine for 30 min, and then in the absence or presence of 3 mM ATP
for ((a) and (b)) 20 min or (c) 5 min in the presence of 25 𝜇M ethidium bromide. (a) The IL-1𝛽 concentration in cell-free supernatants was
measured using an ELISA. (b) The LDH activity in cell-free supernatants and cell lysates was measured using a cytotoxicity kit, and results are
expressed as a percentage of maximal LDH release from lysed cells. (c) Ethidium+ uptake was measured by flow cytometry and is expressed
as mean fluorescence intensity (MFI). ((a) to (c)) Results are mean ± SD (𝑛 = 3); ∗ 𝑃 < 0.05 or ∗∗∗ 𝑃 < 0.001 compared with corresponding
basal; † 𝑃 < 0.05 or ††† 𝑃 < 0.001 compared with DMSO and ATP.

enhance P2X7-induced IL-1𝛽 release is independent of cell
rupture.
The mechanism by which NAI and NAI-imine enhance
P2X7-induced IL-1𝛽 release remains unknown. N-alkyl-substituted isatins inhibit the polymerization of purified bovine
neuronal tubulin and enhance microtubule fragmentation
in human U937 lymphoma cells [18]. This suggests that

NAI and NAI-imine may impair microtubule formation to
enhance P2X7-induced IL-1𝛽 release from J774 macrophages.
In contrast, others have shown that colchicine and nocodazole (which disrupt microtubules) and suberoylanilide
hydroxamic acid and ITF2357 (which impair tubulin hyperacetylation) prevent P2X7-induced IL-1𝛽 release [8–10],
while the microtubule stabilizing agent, paclitaxel, augments

Cell viability (percent of control)
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Figure 5: NAI and NAI-imine induces cytotoxicity in a concentration-dependent manner. LPS-primed J774 cells in complete
medium were incubated with ATP, NAI, or NAI-imine (as indicated)
for 24 h and then with CellTiter 96 AQUEOUS One Solution for
2 h. The viability of cells incubated with ATP or isatin derivatives
was determined as percentage of the maximal absorbance of cells
incubated in the absence of ATP or in the presence of DMSO,
respectively. Results are mean ± SD (𝑛 = 3).

P2X7-induced IL-1𝛽 release [10]. Reasons for differences
between these previous studies and the current study remain
unknown.
The presence of the methoxybenzyl group at the N1
position of NAI and NAI-imine appears to be important
for enhanced P2X7-induced IL-1𝛽 release. As the parent
molecule, 5,7-dibromoisatin, had minimal effect on P2X7induced IL-1𝛽 release. Similarly, 1N-methylisatin had no
effect on P2X7-induced IL-1𝛽 release, highlighting the importance of the chain length and/or hydrophobicity at N1 for
activity. Despite reports of anti-inflammatory actions of isatin
and various isatin derivatives [14], the compounds tested in
the current study did not impair P2X7-induced IL-1𝛽 release.
However, it should be noted that the anti-inflammatory
actions of isatin and isatin derivatives in vitro [32] are
observed at concentrations greater than those used in the
current study (30–100 𝜇M versus 1 𝜇M, resp.).
Finally, the current study demonstrates that 24-hour
incubation with NAI and NAI-imine (in the absence of
exogenous ATP) induces the death of LPS-primed J774
macrophages with IC50 values of 279 nM and 442 nM, respectively. These IC50 values are half that required to kill human
MDA-MB-231 breast cancer and Jurkat lymphoma cell lines
and one log lower for human MCF-7 breast cancer and
U937 lymphoma cell lines and human colon, pancreatic, and
skin cell lines, when examined using the same cytotoxicity
assay [18, 19] as used in the current study. Notably, the
twofold difference in the IC50 values between NAI and NAIimine for J774 cells is also observed for both MDA-MB-231
and MCF-7 cells [19] suggesting that the presence of the

para-phenylpropionic acid linker partly impairs the cytotoxic
efficacy of NAI-imine compared to NAI. Nevertheless, this
imine-based linker is useful for conjugation to targeting
molecules to greatly increase the uptake and cytotoxic efficacy
of NAI-imine [19].
The capacity of NAI and NAI-imine to enhance P2X7induced IL-1𝛽 release from macrophages may have implications in cancer therapy. Various chemotherapeutic agents
can cause ATP release from cancer cells [33], which in
turn activates P2X7 in a paracrine manner to mediate IL1𝛽 release from antigen presenting cells to promote antitumor immunity [34]. Thus, the possibility remains is that, in
addition to NAI-containing drugs directly killing cancer cells,
these compounds may also cause ATP release, which then
act in concert to promote P2X7-induced IL-1𝛽 release and
drive antitumor immunity. Alternatively, but not mutually
exclusive to this, given that NAI and NAI-imine induce
macrophage death, NAI-containing drugs may selectively kill
tumor-associated macrophages, which have the capacity to
promote tumorigenesis [35]. Thereby, providing an additional
mechanism by which these compounds acts as anticancer
agents. Finally, it should be noted that in the absence of
exogenous LPS or ATP, colchicine and other microtubule
destabilizers can increase IL-1𝛽 (and IL-1𝛼) mRNA expression and protein production in human monocytes at 4 h and
18 h of incubation, respectively [36, 37]. Thus, the current
and previous studies indicate time-dependent and other roles
for microtubule destabilizers in IL-1 synthesis and release
and that compounds such as colchicine may also mediate
antitumor effects through both cytotoxicity of tumor cells and
promotion of antitumor immune responses.
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